StockData
Nyxoah SA logo

Nyxoah SA (NYXH) stock

NYXHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 26, 2026Score 1/30
$0.90+0.01 (+0.69%)

Close on Nov 17, 2026Market cap $38.72MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026

Valuation

Market cap
€35.09M
P/E ratio
–
Price to sales
–
Price to book
0.42
Dividend yield
–
Free cash flow yield
-198.87%

Fundamentals

Net income
-€90.09M
EPS, diluted
-2.36 EUR
Free cash flow
-€69.78M
Book value per share
1.46 EUR
Diluted shares
57M

Trading

Previous close
$0.89
Open
$0.90
Day's range
$0.87 – $0.90
Volume
23,011
Average volume (20 days)
237,845
RSI (14 days)
38.5
Volatility (1 year)
83.7%
Relative volume
0.09×

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodNYXHS&P 500DifferenceNYXH per yearS&P 500 per year
1 month-18.9%-4.0%−14.9 pts
3 months-43.8%-5.0%−38.8 pts
Year to date-80.4%+8.2%−88.7 pts
1 year-81.1%+11.2%−92.3 pts
3 years-82.1%+68.5%−150.6 pts-43.6%+19.0%
5 years-96.1%+67.3%−163.3 pts-47.6%+10.8%

Eight years at a glance

Fiscal years 2018 to 2025, EUR

Gross profit

€6.33M+113.1% YoY

Operating income

-€83.49M

Net income

-€90.09M

EPS, diluted

-2.36 EUR

Free cash flow

-€69.78M
Reported period

Press releases

Releases Nyxoah filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Nyxoah

Surgical & Medical Instruments & Apparatus

Nyxoah is a medical technology company focused on developing and commercializing therapeutic solutions for obstructive sleep apnea. Its primary product is the Genio system, a leadless hypoglossal neurostimulation device that delivers bilateral stimulation to keep upper airways open during sleep. The system is implanted through a single incision under the chin and operates using an external power source. The company primarily targets adult patients diagnosed with moderate to severe obstructive sleep apnea who cannot tolerate, fail, or refuse positive airway pressure therapies, marketed through hospitals and physicians such as sleep specialists and ear, nose, and throat doctors.

Company profile, executives and history

Nyxoah stock: common questions

What is Nyxoah's stock price?

NYXH closed at $0.90 on Nov 17, 2026, up 0.69% on the day.

What is Nyxoah's market cap?

Nyxoah was worth $38.72M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is NYXH's P/E ratio?

Nyxoah lost money over fiscal 2025 (diluted EPS -2.36 EUR), so it has no meaningful P/E ratio.

Does Nyxoah pay a dividend?

No. Nyxoah has not paid a cash dividend over the last twelve months.

How has NYXH stock performed over the past year?

Including dividends, NYXH returned -81.1% over the past year, against +11.2% for the S&P 500.

Who are Nyxoah's competitors?

Companies most similar to Nyxoah by business, industry and size include INSP, VVOS, LUNG, CVRX, BWAY.

See a number that looks wrong?